Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America
Dunlay SM, Givertz MM, Aguilar D, et al.
Circulation. 2019 Jun 6:CIR0000000000000691.
Leggi
Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab – A post hoc analysis of the Protocol T randomized clinical trial
Bressler NM, Odia I, Maguire M, et al.
JAMA Ophthalmol. 2019 Jun 27
Leggi
Quantifying the impact of genes on body mass index during the obesity epidemic: longitudinal findings from the HUNT Study
Brandkvist M, Bjørngaard JH, Ødegård RAi, et al.
BMJ 2019;366:l4067
Leggi
Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies
Neuenschwander M, Ballon A, Weber KS, et al.
BMJ 2019;366:l2368
Leggi
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Esser N, Zraika S
Diabetologia. 2019;62:1113–22
Leggi
Comunicato stampa diffuso da AMD, Fondazione AMD e Diabete Italia sul caso Panzironi
Clicca qui per scaricare il comunicato stampa.
Leggi
Dietary patterns are not associated with brain atrophy or cerebral small vessel disease in older adults with and without type 2 diabetes
Zabetian-Targhi F, Srikanth VK, Smith KJ, et al.
J Nutr. 2019 Jun 29
Leggi
AIFA – FDA approva un nuovo trattamento per i pazienti pediatrici con diabete di tipo 2
27/06/2019
Leggi
Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies
Kristensen K, Ögge LE, Sengpiel V, et al.
Diabetologia. 2019;62:1143–53
Leggi
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Heerspink HJL, Perco P, Mulder S, et al.
Diabetologia. 2019;62:1154–66
Leggi